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Abstract  
Junctional Adhesion Molecule-A (JAM-A) is a membranous cell-cell adhesion protein 
involved in tight junction formation in epithelial and endothelial cells. Its over-expression in 
breast tumors has recently been linked with increased risk of metastasis. We sought to 
identify if JAM-A over-expression was associated with specific subtypes of breast cancer as 
defined by expression of human epidermal growth factor receptor-2 (HER2), estrogen 
receptor (ER) and progesterone receptor (PR). To this end, JAM-A immunohistochemistry 
was performed in two breast cancer tissue microarrays. In parallel, cross-talk between JAM-
A, HER2 and ER was examined in several breast cell lines using complementary genetic and 
pharmacological approaches. High JAM-A expression correlated significantly with HER2 
protein expression, ER-negativity, lower patient age, high grade breast cancers and aggressive 
luminal B, HER2 and basal subtypes of breast cancer. JAM-A and HER2 were co-expressed 
at high levels in vitro in SKBR3, UACC-812, UACC-893 and MCF7-HER2 cells. 
Knockdown or functional antagonism of HER2 did not alter JAM-A expression in any cell 
line tested. Interestingly however, JAM-A knockdown decreased HER2 and ER-α expression, 
resulting in reduced levels of phospho- (active) AKT without effect on ERK phosphorylation. 
The downstream effects of JAM-A knockdown were reversed upon treatment with the 
proteasomal inhibitor MG132. We conclude that JAM-A is co-expressed with HER2 and 
associates with aggressive breast cancer phenotypes. Furthermore we present novel evidence 
that JAM-A regulates HER2 proteasomal degradation and activity, suggesting that JAM-A 
may offer promise as a therapeutic target in HER2-positive breast cancers. 
 
Key words: junctional adhesion molecule-A; breast cancer; tight junction; human epidermal 
growth factor receptor 2, AKT, estrogen receptor 
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Introduction  
Breast cancer is the most common form of cancer among women in North America and 
Europe. Each year it is diagnosed in over 1 million women worldwide, and is the cause of 
death of over 450,000 (Ferlay J, 2010). A major challenge in breast cancer treatment is to 
identify those patients most likely to develop recurrence so that appropriate therapy can be 
selected. Genomic studies have established five major breast cancer intrinsic subtypes 
(luminal A, luminal B, HER2-enriched, basal-like and claudin-low) and a normal breast-like 
group that show significant differences in incidence, survival and response to therapy (Carey 
et al., 2006; Herschkowitz et al., 2007; Perou et al., 2000; Sorlie et al., 2001).  
 
Estrogen receptor (ER)-negative (HER2-enriched, basal-like and claudin-low) subtypes are 
associated with an increased risk of aggressive metastatic disease when compared to luminal 
(ER-positive) subtypes. HER2 is amplified in 20–30% of invasive breast cancers, which 
represent the luminal B and HER2-enriched subtypes (Slamon et al., 1987). HER2 oncogenic 
properties are thought to result from increased activation of several signaling pathways 
including the extracellular signal-related kinase (ERK) cascade and the phosphoinositide 3-
kinase (PI3K)-AKT pathway (Baselga and Swain, 2009). Therapeutic inhibition of HER2 
function has been successfully applied to treat patients with HER2-positive breast cancer 
(Geyer et al., 2006; Piccart-Gebhart et al., 2005; Romond et al., 2005); however the efficacy 
of such strategies is limited by primary and acquired resistance (Baselga and Swain, 2009).  
 
Growth factor receptors are not the only membrane proteins of interest in the pathophysiology 
of breast cancer. Tight junction (TJ) proteins such as JAM-A, CAR, claudin -3 and -4 have 
been shown to be over-expressed in breast cancer (Hewitt et al., 2006; Hoevel et al., 2004; 
Lanigan et al., 2009; Martin et al., 2005; McSherry et al., 2009; Osanai et al., 2007a; Osanai 
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et al., 2007b), and may represent novel therapeutic targets. In normal breast tissue these 
proteins are expressed at lower levels and confined predominately to areas of epithelial cell-
cell contact. Enhanced expression in tumor cells may make TJ proteins interesting candidates 
for targeted delivery of cytotoxic agents, or for downregulation of signaling pathways related 
to oncogenic functions. 
 
TJs along with adherens junctions form the apical junctional complex, which encircles the 
apex of epithelial and endothelial cells and acts to maintain cell polarity by separating apical 
and basolateral compartments (Nelson, 2003). Of primary interest in our study is the TJ 
protein JAM-A, which has important functions in cellular adhesive processes including TJ 
assembly (Liang et al., 2000), cellular polarity (Ebnet et al., 2001), the regulation of cell 
morphology (Mandell et al., 2005), angiogenesis (Cooke et al., 2006), platelet activation 
(Babinska et al., 2002) and leukocyte migration (Ostermann et al., 2002). We (McSherry et 
al., 2009) and others (Murakami et al., 2011) recently identified a significant association 
between JAM-A over-expression and poor prognosis of breast cancer patients. Furthermore 
JAM-A has been demonstrated to be a target of the microRNA miR-145, which is 
downregulated in breast cancer and whose over-expression decreases motility and invasive 
behavior in breast cancer cells (Gotte et al., 2010). 
 
In this study we therefore sought to refine the link between JAM-A and aggressive tumor 
behavior using breast cancer clinical datasets in conjunction with in vitro cell line models. We 
report that high JAM-A expression correlates significantly with HER2 protein expression, 
ER-negativity and high grade breast cancers. In breast cell lines co-expressing JAM-A and 
HER2, we present novel evidence that HER2 knockdown or pharmacological antagonism 
does not influence JAM-A protein expression, whereas JAM-A knockdown reduces that of 
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HER2 and ER-α via a pathway involving the proteasome. JAM-A knockdown also exerts a 
selective effect on signaling through HER2 effector pathways, demonstrated as reductions in 
AKT but not ERK phosphorylation. Collectively, our results suggest that JAM-A is a novel 
upstream regulator of HER2 degradation and activity, and that its overexpression may 
promote breast cancer progression in HER2-positive tumors. We submit that JAM-A offers 
promise not just as a novel biomarker of the HER2-positive breast cancer phenotype, but also 
as a drug target of the future. 
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Results and discussion 
The intercellular adhesion protein JAM-A is expressed as a homodimer on epithelial and 
endothelial cell surfaces and has been shown to have important physiological functions in 
numerous cellular adhesive processes. We and others have recently linked high breast 
epithelial expression of JAM-A with aggressive disease and poor outcome in breast cancer 
patients (Gotte et al., 2010; McSherry et al., 2011; McSherry et al., 2009; Murakami et al., 
2011). We independently verified these findings on a small breast cancer TMA of 48 tumor 
cores, in which tissue cores were scored 0, 1+, 2+ or 3+ according to the level of membranous 
JAM-A staining in tumor cells (Supplemental Fig. S1). JAM-A expression was classified as 
low [0 or 1+] in 28 tumors (58.3%) and high [2+ or 3+] in 20 tumors (41.7%). High JAM-A 
expression was significantly associated with low progesterone receptor (PR) expression 
(p<0.05), invasive breast cancers (p<0.05), HER2+/ER-/PR- expressing breast cancers 
(p<0.05) and breast tumors of ≥2cm in diameter (p<0.05; Supplemental Table 1). 
 
To further interrogate the sub-types of aggressive tumors associated with high JAM-A 
expression, we analyzed a larger TMA of 167 tumor cores with known HER2 expression 
status. Tumor membranous expression of JAM-A was classified as low [0 or 1+] in 75 tumors 
(44.9%) and high [2+ or 3+] in 92 tumors (55.1%). Examination of the relationship between 
JAM-A expression and other clinicopathological variables (Table 1) as examined by χ2 test 
and Fisher’s exact tests on SPSS version 15.0 revealed that high JAM-A expression was 
significantly associated with HER2 protein expression (p<0.05), high tumor grade (p<0.001) 
and ER-negativity (p<0.001). According to one molecular classification of breast cancers 
(Sorlie et al., 2001), high JAM-A levels were also associated with the HER2+ and basal 
subtypes of breast cancer (p<0.05). These data indicate that high JAM-A expression in breast 
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cancer is associated with aggressive breast tumor characteristics, and highlights a role for 
JAM-A as a possible biomarker.  
. 
Since breast cancer is a heterogeneous disease, we screened JAM-A protein levels in a range 
of cell lines expressing different profiles of the clinicopathologically-relevant molecular 
markers HER2 and ER-α (Supplemental Fig. S2). All the HER2-positive cell lines expressed 
moderate to high levels of JAM-A, while the basal-like ER-/HER2-negative cell line MDA-
MB-231 expressed low levels of JAM-A. As JAM-A expression was high in several HER2-
positive breast cancer cell lines, we questioned whether expression levels of one protein could 
regulate those of the other. We first knocked down HER2 expression in several breast cancer 
cell lines using an siRNA approach. As shown by densitometric quantitation in Fig. 1, HER2 
was successfully knocked down in SKBR3, UACC-893, MCF7-HER2 and LCC1 cells. A 
representative Western blot for UACC-893 cells is shown. HER2 knockdown had no effect on 
JAM-A protein expression in the ER-negative cell lines SKBR3 and UACC-893. 
Interestingly, however, there was a partial reduction in JAM-A protein expression following 
HER2 knockdown in the ER-positive cell lines MCF7-HER2 (Pegram et al., 1997) and 
LCC1; Fig. 1A).  
 
Subtle reductions in JAM-A expression secondary to HER2 knockdown in ER-positive cells 
suggested that JAM-A expression levels may be regulated by those of ER-α. We thus knocked 
down ER-α in conjunction with HER2 in MCF7-HER2 and LCC1 cells to examine if JAM-A 
expression could be restored. As shown in the densitometric quantitation in Fig. 1B, ER-α 
knockdown either alone or in conjunction with HER2 knockdown did not alter JAM-A 
protein expression in either cell line. A representative blot from LCC1 cells is shown. 
Furthermore chemical inhibition of HER2 with AG825 (Fig. 1C), inhibition of ER-α with 
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tamoxifen (OHT) or stimulation with 17-β-estadiol (E2; Fig. 1D) did not significantly alter 
JAM-A expression in MCF7-HER2 cells. 
 
Having observed no regulation of JAM-A protein expression following manipulation of 
HER2 or ER-α, we next tested the opposite strategy. JAM-A was transiently knocked down 
by siRNA in SKBR3, UACC-893, MCF7-HER2 and LCC1 cells. As shown by densitometric 
quantitation of western blots (Fig 2A graph), JAM-A protein expression was successfully 
reduced in all cell lines after 72h. HER2 protein expression was partially but not significantly 
reduced by knockdown of JAM-A in ER-negative SKBR3 and UACC-893 cells. However 
HER2 and ER-α protein expression were both significantly reduced following knockdown of 
JAM-A in ER-positive MCF7-HER2 and LCC1 cells (Fig 2A graph). A representative blot 
from LCC-1 cells is shown. We also tested whether functional antagonism of JAM-A using 
the dimerisation-blocking antibody J10.4 could influence HER2 protein expression in SKBR3 
or UACC-893 cells. As shown in Fig. 2B (graph), J10.4 had no effect on the expression levels 
of JAM-A, HER2 or Y1221-phosphorylated HER2 in either cell line. A representative blot 
from UACC-893 cells is shown. 
 
Following our observation that HER2 and ER-α protein expression was reduced upon 
knockdown of JAM-A, we next examined whether JAM-A knockdown caused increased 
turnover of ER-α, HER2 and its effectors AKT and ERK. JAM-A was transiently knocked 
down by siRNA in MCF7-HER2 cells, whereupon we noted not only a significant reduction 
in HER2 and ER-α expression but also that of phospho-AKT (DMSO condition in Fig. 3A, 
quantitation in Fig. 3B). In contrast there was a variable increase in ERK phosphorylation in 
response to JAM-A knockdown, but this was not statistically significant. To test whether 
reductions in HER2 and pAKT expression downstream of JAM-A knockdown reflected 
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proteasomal degradation, cells were treated with the proteasomal inhibitor MG132 4 hours 
prior to lysis. The protein expression of HER2, ER-α and phospho-AKT was restored by 
MG132 treatment of JAM-A knockdown cells (Fig. 3C). However phospho-ERK levels was 
not restored under the same conditions. This suggested that the mechanism whereby JAM-A 
expression regulates that of HER2 and ER-α is through alteration of proteasomal degradation. 
This adds to increasing evidence that JAM-A regulates protein turnover through proteasomal 
degradation, as JAM-A knockdown has previously been shown to similarly reduce the protein 
expression of β1-integrin (McSherry et al., 2011; McSherry et al., 2009; Severson et al., 
2009) and αV- and α5-integrin (McSherry et al., 2011). Further studies are required to 
determine the specific proteasomal components implicated, but it is intriguing to speculate 
that JAM-A may also have the capability to likewise regulate the expression of other growth 
factor receptors/adhesion molecules relevant to breast cancer progression.  
 
Interestingly, the HER2 effectors AKT and ERK were differentially regulated downstream of 
JAM-A manipulation in our models. Specifically, AKT phosphorylation was significantly 
reduced upon JAM-A knockdown and restored following proteasomal inhibition, whereas 
ERK phosphorylation was not. A similar regulation of HER2 signaling has been reported 
following adenine nucleotide translocase 2 (ANT2) knockdown, which increases HER2 
degradation through suppression of HSP90 functions, and results in inhibition of the 
PI3K/AKT signaling pathway (Jang et al.). Active AKT has also been shown to regulate ERK 
activation by phosphorylating and inhibiting Raf-1, a kinase which activates ERK through 
MEK (Zimmermann and Moelling, 1999). Our results suggest that JAM-A knockdown 
regulates AKT indirectly by reducing HER2 protein expression. AKT has been shown to 
promote cancer cell invasion, cell survival, increased motility and metalloproteinase 
production as well as promoting resistance to trastuzumab and tamoxifen in breast cancer 
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cells (Brunet et al., 1999; Clark et al., 2002; Kim et al., 2001). Thus one might predict that 
the over-expression of JAM-A in aggressive breast cancers (McSherry et al., 2009) is 
associated with increased levels of AKT activity which promote survival and motility. 
Furthermore the pharmacological reduction of JAM-A signaling may have benefit in reducing 
metastatic risk, since we (McSherry et al., 2011; McSherry et al., 2009) and others (Gotte et 
al., 2010) have shown that JAM-A knockdown or functional antagonism decreases breast 
cancer cell migration, an early event in metastasis. 
 
It is interesting to note that ER-α expression was regulated by JAM-A in the ER-positive cell 
lines tested, whereas our TMA data demonstrated a link between high JAM-A expression and 
ER-α negativity. Based on TMA data we had hypothesized that ER would negatively regulate 
JAM-A expression, yet pharmacological interference with ER-α signaling using estrogen or 
tamoxifen did not regulate JAM-A expression in the cell lines tested. This intriguing 
difference illustrates the importance of considering cell line data in conjunction with more 
pathophysiologically-representative tissue data from a large number of patients. However 
since stimulation of ER-β with estrogen has been shown to upregulate JAM-A in intestinal 
cells (Braniste et al., 2009), we speculate that a level of unexplored crosstalk exists. Given the 
functionally opposing roles of ER-α and –β in breast tissue, it is possible that ER-α negative 
tissue may express ER-β, however a larger ER-negative cohort of tissue samples would be 
needed to answer this question. 
 
In conclusion, we have shown that JAM-A is upregulated in HER2-positive, ER-negative 
breast cancers and associated with more aggressive breast cancers. While high JAM-A 
expression in tissue microarrays correlates with ER negativity, we show for the first time that 
JAM-A regulates HER2 and ER-α proteasomal degradation in breast cell lines. Our data also 
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indicate that observed reductions in HER2 downstream of JAM-A prevent downstream 
activation of AKT. This effect on AKT following JAM-A knockdown suggests that 
therapeutics targeting JAM-A expression or signaling may offer new treatment options for 
aggressive tumors over-expressing JAM-A and/or HER2. 
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FIGURE LEGENDS 
Figure 1: HER2 or ERα knockdown do not regulate JAM-A expression 
(A) Graph: Densitometric quantitation of HER2 and JAM-A protein expression in UACC-
893, MCF7-HER2 and LCC1 breast cells transfected for 72h with 25nM of control siRNA 
(siGENOME non-targeting siRNA #1, Dharmacon/Thermo Scientific, Epsom, UK) or HER2 
siRNA (Dharmacon) using the Dharmafect-1 siRNA transfection system (Dharmacon). Cell 
extracts were separated by SDS–PAGE and immunoblotted with anti-human JAM-A (Zymed 
Laboratories Inc., Invitrogen, CA, USA), HER2 (Cell Signaling Technologies, MA, USA) or 
actin (Abcam, Cambridge, UK) antibodies. A representative Western blot from UACC-893 
cells is shown. (B) Graph: Densitometric quantitation of JAM-A, ER-α and HER2 protein 
expression in ER-positive MCF7-HER2 and LCC1 cells transfected for 72h with 25nM of 
control siRNA (siGENOME non-targeting siRNA #1, Dharmacon), ER-α siRNA  (Ambion, 
Life Technologies, USA) or ER-α + HER2 siRNA using the Dharmafect-1 siRNA 
transfection system. Cell extracts were separated by SDS–PAGE and immunoblotted with 
anti-human JAM-A, HER2, ERα (Santa Cruz, CA, USA) or actin antibodies. A representative 
Western blot from LCC1 cells is shown. (C) Western blot analysis of JAM-A, ER-α and 
HER2 protein expression in MCF7-HER2 cells treated for 6 hours with vehicle or the HER2 
inhibitor AG825 (100μM; Sigma-Aldrich, Poole, UK). Cell extracts were separated by SDS–
PAGE and immunoblotted with anti-human HER2-p-1221/1222 (Cell Signaling 
Technologies, MA, USA), HER2, p-ERK (Cell Signaling Technologies, MA, USA), ERK 
(Cell Signaling Technologies, MA, USA), JAM-A or actin antibodies. A representative 
Western blot from MCF7-HER2 cells is shown. (D)  Western blot analysis of JAM-A 
expression in MCF7 cells treated for 24 hours with vehicle, 17β-estradiol (E2, 10nM; Sigma-
Aldrich, Poole, UK), tamoxifen (100nM Sigma-Aldrich, Poole, UK) or a combination of both, 
following preincubation in phenol red-free media containing 10% charcoal dextran-stripped 
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FBS. Cell extracts were separated by SDS–PAGE and immunoblotted with anti-human JAM-
A and actin antibodies. A representative Western blot from MCF7 cells is shown. In all 
graphs, error bars refer to standard error of the mean of triplicate experiments. 
 
Figure 2: JAM-A knockdown but not antagonism reduces HER2 and ERα protein 
expression 
(A) Graph: Densitometric quantitation of JAM-A, ERα and HER2 protein expression in 
SKBR3, UACC-893 cells transfected for 72h with 75nM of control siRNA (MISSION® 
siRNA Universal Negative control #1, Sigma-Aldrich, Poole, UK) or JAM-A siRNA 
(SASI_Hs01_00049785, Sigma-Aldrich, Poole, UK) using the N-TER nanoparticle siRNA 
transfection system (Sigma-Aldrich, Poole, UK). MCF7-HER2 and LCC1 cells transfected 
for 72h with 25nM of control siRNA (siGENOME non-targeting siRNA #1, Dharmacon) or 
JAM-A siRNA (SASI_Hs01_00049785, Sigma-Aldrich, Poole, UK) using the Dharmafect-1 
siRNA transfection system. Cell extracts were run on SDS–PAGE and immunoblotted with 
anti-human JAM-A, HER2, ERα and actin antibodies. A representative Western blot from 
LCC1 cells is shown. (B) Graph: Densitometric quantitation of JAM-A, pHER2 (Y-1221) and 
HER2 protein expression in SKBR3, UACC-893 cells treated for 72h with 10μg/ml JAM-A 
inhibitory antibody J10.4 or control mouse IgG (sodium azide- and gelatin-free; Santa Cruz, 
CA, USA). Cell extracts were separated by SDS–PAGE and immunoblotted with anti-human 
JAM-A, HER2-p-1221/1222, HER2 and actin antibodies. A representative Western blot from 
UACC-893 cells is shown. Error bars refer to standard error of the mean of triplicate 
experiments (***p<0.001 by two-tailed unpaired student’s t-test). 
 
Figure 3: JAM-A regulates HER2 degradation and downstream AKT activation  
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(A) Western blot analysis of JAM-A, ER-α, HER2, p-AKT S473, total AKT, p-ERK and total 
ERK protein expression in MCF7-HER2 cells transfected for 72h with 25nM of control 
siRNA (siGENOME non-targeting siRNA #1, Dharmacon) or JAM-A siRNA 
(SASI_Hs01_00049785, Sigma-Aldrich, Poole, UK) using the Dharmafect-1 siRNA 
transfection system. Vehicle control (DMSO) or the proteosomal inhibitor MG132 (10μM) 
were present for the final 4h. Cell extracts were separated by SDS–PAGE and immunoblotted 
with anti-human JAM-A, HER2, ERα, p-AKT-S473 (Cell Signaling Technologies, MA, 
USA), AKT (Cell Signaling Technologies, MA, USA), p-ERK, ERK and actin antibodies. (B) 
Densitometric quantification of the effects of JAM-A knockdown alone (DMSO condition). 
HER2, ER-α and p-AKT protein levels were significantly reduced (*p<0.05, ***p<0.001 by 
two-tailed unpaired student’s t-test).  (C) Densitometric quantification of the effects of 
MG132 treatment relative to DMSO conditions. Protein levels of HER2, ER-α and p-AKT 
(reduced upon JAM-A knockdown) were partially restored following proteasomal inhibition. 
In all graphs, error bars refer to standard error of the mean of triplicate experiments. 
 
Supplemental Figure S1: JAM-A immunohistochemical staining in breast cancer tissue 
microarrays  
JAM-A immunohistochemistry (IHC) was performed as we have previously described 
(McSherry et al., 2009) on 4µm sections of two separate formalin-fixed paraffin-embedded 
TMAs totaling respectively 48 and 167 invasive breast cancers. Membranous expression of 
JAM-A in tumor cells was scored 0, 1+, 2+ or 3+ based on staining intensity. JAM-A results 
were scored by four independent observers including one pathologist. Scale bar; 5µm. 
 
Supplemental Figure S2: Western blot analysis of JAM-A, HER2 and phospho-HER2 
expression across a range of breast cancer cell lines. 
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Western blot analysis of JAM-A, HER2, p Y877-phospho-HER2 and Y1221-phospho-HER2 
protein expression in a range of cell lines expressing different profiles of the 
clinicopathologically-relevant molecular markers HER2 and ER-α. Cell extracts were 
separated by SDS–PAGE and immunoblotted with anti-human JAM-A, HER2-p-1221/1222, 
HER2-p-877 (Cell Signaling Technologies, MA, USA), HER2 and actin antibodies. 
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